Gilling Peter J, Aho Tevita F, Frampton Christopher M, King Colleen J, Fraundorfer Mark R
Department of Urology, Tauranga Hospital, Tauranga, New Zealand.
Eur Urol. 2008 Apr;53(4):744-9. doi: 10.1016/j.eururo.2007.04.052. Epub 2007 Apr 23.
The issue of durability is an important concern when evaluating new surgical modalities. To date, only 24-mo data have been published on holmium enucleation of the prostate (HoLEP) despite its widespread use worldwide although 4-yr data exist for the earlier technique of holmium resection. This study addresses the issue of durability of HoLEP.
All patients who had undergone HoLEP and been evaluated in three prospective trials conducted at this institution between 1997 and 2002 were evaluated. Patients available at follow-up had data assessed on the International Prostate Symptom Score (IPSS), maximal flow rate (Qmax), quality of life (QOL), International Continence Society Male Short Form (ICS-SF), International Index of Erectile Function (IIEF), Benign Prostatic Hyperplasia Impact Index (BPHII), and continence questionnaire.
The mean follow-up was 6.1 yr (range: 4.1-8.1 yr). The mean age of the patients at follow-up was 75.7 yr (range: 58-88 yr). Of 71 HoLEP patients originally studied on the protocol, 38 (54%) were available for analysis, 14 were deceased, and 19 were lost to follow-up. The mean IPSS for this group was 8.5 (range: 0-24) and Q(max) 19 ml/s (range: 6-28 ml/s). The QOL score was 1.8 (range: 0-5) and the BPHII 2.0 (range: 0-11). One patient (1.4%) had undergone reoperation, an additional HoLEP. Overall, 92% were either satisfied or extremely satisfied with their outcome.
HoLEP is durable and most patients remain satisfied or extremely satisfied with the long-term outcome.
在评估新的手术方式时,耐久性问题是一个重要关注点。尽管钬激光前列腺剜除术(HoLEP)在全球广泛应用,但迄今为止,关于该手术方式仅发表了24个月的数据,而早期的钬激光切除术有4年的数据。本研究探讨HoLEP的耐久性问题。
对1997年至2002年在本机构进行的三项前瞻性试验中接受HoLEP治疗并接受评估的所有患者进行评估。随访时可获得的患者数据包括国际前列腺症状评分(IPSS)、最大尿流率(Qmax)、生活质量(QOL)、国际尿失禁学会男性简表(ICS-SF)、国际勃起功能指数(IIEF)、良性前列腺增生影响指数(BPHII)以及尿失禁问卷。
平均随访时间为6.1年(范围:4.1 - 8.1年)。随访时患者的平均年龄为75.7岁(范围:58 - 88岁)。最初纳入研究方案的71例HoLEP患者中,38例(54%)可用于分析,14例死亡,19例失访。该组的平均IPSS为8.5(范围:0 - 24),Qmax为19 ml/s(范围:6 - 28 ml/s)。QOL评分为1.8(范围:0 - 5),BPHII为2.0(范围:0 - 11)。1例患者(1.4%)接受了再次手术,即再次进行HoLEP手术。总体而言,92%的患者对其手术结果感到满意或极其满意。
HoLEP具有耐久性,大多数患者对长期结果仍感到满意或极其满意。